Since 2024, Zypadhera (powder and solvent for prolonged release suspension for injection) has been subject to limited availability. Availability has since improved. Therefore, distribution restrictions have been be gradually and carefully relaxed since 1 January 2026. The FAMHP Task Force Unavailability issues recommendations with a view to further easing.
FAMHP (Belgian Medicine Agency)
Improved availability of Zypadhera powder and solvent for prolonged release suspension for injection: relaxation of restrictions and updated recommendations
Original title: Improved availability of Zypadhera powder and solvent for prolonged release suspension for injection: relaxation of restrictions and updated recommendations for physicians (specialists), pharmacists (hospital and community) and patients
Distribution restrictions on Zypadhera have been gradually relaxed since 1 January 2026 as availability improves.
Applies from
2026-01-01
Published by FAMHP (Belgian Medicine Agency). HealthSignal links to the original document; the summary above is extracted from the source text.